Cleveland Clinic researchers have won $11.7 million from the National Institutes of Health (NIH) to find out why "good" cholesterol sometimes goes bad, and then to harness their discoveries as new diagnostic tests or therapies for heart disease.
The Cleveland Clinic will work with Esperion Therapeutics Inc. to develop “good cholesterol” therapies to fight cardiovascular disease. Privately held biopharmaceutical company Esperion in Plymouth, Mich. — which discovers, develops and commercializes therapies for cardiovascular diseases — announced its “collaborative research agreement” with the Clinic — the nation’s leading heart medical center — on Monday. […]
